Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Gynecology

Free Subscription Articles published in Lancet Retrieve available abstracts of 78 articles: HTML format

Single Articles

December 2025
1. NASH Z, Christmas M, Gronlund T, Hickey M, et al
   Top ten menopause research priorities.
   Lancet. 2025;404:2535-2536.
   PubMed    
   
   
   
2. TONG S, Cluver CA, Walker SP
   Reducing term pre-eclampsia by 30%: is it possible?
   Lancet. 2025 Dec 4:S0140-6736(25)01672-1. doi: 10.1016/S0140-6736(25)01672.
   PubMed    
   
   
   
3. GOADSBY J, Syngelaki A, Magee LA, von Dadelszen P, et al
   Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.
   Lancet. 2025 Dec 4:S0140-6736(25)01207-3. doi: 10.1016/S0140-6736(25)01207.
   PubMed     Abstract available
   
   
   November 2025
4. NANA M, Painter R, Williamson C, Nelson-Piercy C, et al
   Hyperemesis gravidarum.
   Lancet. 2025 Nov 13:S0140-6736(25)01454-0. doi: 10.1016/S0140-6736(25)01454.
   PubMed     Abstract available
   
   
   
5. ANDERSON DJ, Bearak JM, Grimstad FW, Palanee-Phillips T, et al
   Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive health.
   Lancet. 2025;406:2119-2132.
   PubMed     Abstract available
   
   
   October 2025
6. SURYAWANSHI H, Gemmell LC, Morgan S, Koustas G, et al
   First clinical pregnancy following AI-based microfluidic sperm detection and recovery in non-obstructive azoospermia.
   Lancet. 2025 Oct 31:S0140-6736(25)01623-X. doi: 10.1016/S0140-6736(25)01623.
   PubMed    
   
   
   
7. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
   Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
   Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
   PubMed     Abstract available
   
   
   
8. BEKKER LG, Joseph Davey D, Saidi F
   Two for two: lenacapavir during pregnancy and lactation.
   Lancet. 2025;406:1560-1561.
   PubMed    
   
   
   August 2025
9. MCCORMACK M, Eminowicz G, Vaja S, Hackshaw A, et al
   INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.
   Lancet. 2025;406:807.
   PubMed    
   
   
   
10. PETRIC P, Lindegaard JC, Schmid MP, Jurgenliemk-Schulz I, et al
    INTERLACE: not a new standard for cervical cancer chemoradiation.
    Lancet. 2025;406:806-807.
    PubMed    
    
    
    
11. 
    Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    PubMed     Abstract available
    
    
    
12. LIU T, Lu D, Wu X
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial - Authors' reply.
    Lancet. 2025;406:446.
    PubMed    
    
    
    
13. CHENG C
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445.
    PubMed    
    
    
    
14. HUANG L, We Y, Chen F
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445-446.
    PubMed    
    
    
    July 2025
15. BRASIL P, Nielsen-Saines K, Guaraldo L, Fuller T, et al
    A decade later, what have we learned from the Zika epidemic in children with intrauterine exposure?
    Lancet. 2025 Jul 3:S0140-6736(25)00826-8. doi: 10.1016/S0140-6736(25)00826.
    PubMed     Abstract available
    
    
    June 2025
16. HARTER P, Marme F
    Targeting the glucocorticoid receptor in relapsed ovarian cancer: a new pathway and standard treatment option in ovarian cancer.
    Lancet. 2025;405:2180-2182.
    PubMed    
    
    
    
17. DE SMIT NS, de Lange ME, Boomsma MF, Huirne JAF, et al
    Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas.
    Lancet. 2025 Jun 19:S0140-6736(25)00728-7. doi: 10.1016/S0140-6736(25)00728.
    PubMed     Abstract available
    
    
    
18. FERNANDEZ TURIENZO C, November L, Kamara M, Conteh O, et al
    Community-based mentoring to reduce maternal and perinatal mortality in adolescent pregnancies in Sierra Leone (2YoungLives): a pilot cluster-randomised controlled trial.
    Lancet. 2025 Jun 18:S0140-6736(25)00454-4. doi: 10.1016/S0140-6736(25)00454.
    PubMed     Abstract available
    
    
    
19. HODNETT E
    A community-based landmark trial to save the lives of pregnant adolescents and their newborns in sub-Saharan Africa.
    Lancet. 2025 Jun 18:S0140-6736(25)00731-7. doi: 10.1016/S0140-6736(25)00731.
    PubMed    
    
    
    
20. OLAWAIYE AB, Gladieff L, O'Malley DM, Kim JW, et al
    Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
    Lancet. 2025 Jun 2:S0140-6736(25)01040-2. doi: 10.1016/S0140-6736(25)01040.
    PubMed     Abstract available
    
    
    May 2025
21. SCHOENAKER D, Stephenson J, Chakrabarti S, Alloway L, et al
    Prioritising maternal health must include care before pregnancy.
    Lancet. 2025;405:1903.
    PubMed    
    
    
    
22. GARDOSI J, Ewington LJ, Booth K, Bick D, et al
    Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.
    Lancet. 2025 May 1:S0140-6736(25)00162-X. doi: 10.1016/S0140-6736(25)00162.
    PubMed     Abstract available
    
    
    March 2025
23. LAUDANSKI P
    Natural or artificial menstrual cycle for frozen embryo transfer.
    Lancet. 2025;405:893-894.
    PubMed    
    
    
    
24. MAKAMA M, Vogel JP
    Atosiban and managing women in preterm labour.
    Lancet. 2025 Mar 3:S0140-6736(25)00402-7. doi: 10.1016/S0140-6736(25)00402.
    PubMed    
    
    
    February 2025
25. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    PubMed     Abstract available
    
    
    
26. HUGHES H
    Endometriosis: an Australian perspective on encouraging change.
    Lancet. 2025;405:378-379.
    PubMed    
    
    
    
27. DANG L, Mi M, Qiao Y, Zhu L, et al
    Eliminating cervical cancer in the Tibetan Plateau.
    Lancet. 2025;405:375-376.
    PubMed    
    
    
    November 2024
28. LORUSSO D, Yamada K, Li K, Cerrotta A, et al
    Pembrolizumab for locally advanced cervical cancer - Authors' reply.
    Lancet. 2024;404:2051-2052.
    PubMed    
    
    
    
29. DONG B, Lu Y, Wang Y, Sun P, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050.
    PubMed    
    
    
    
30. SCHMID MP, Petric P, Mahantshetty U, Kirisits C, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050-2051.
    PubMed    
    
    
    
31. KAMRAVA M, Beriwal S
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049.
    PubMed    
    
    
    
32. MURAKAMI N, Okonogi N, Terao Y, Shikama N, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049-2050.
    PubMed    
    
    
    
33. 
    Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed     Abstract available
    
    
    October 2024
34. MCCORMACK M, Eminowicz G, Gallardo D, Diez P, et al
    Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    Lancet. 2024;404:1525-1535.
    PubMed     Abstract available
    
    
    
35. DUSKA LR, Randall LM
    Progress in the treatment paradigms for locally advanced cervical cancer.
    Lancet. 2024;404:1494-1496.
    PubMed    
    
    
    
36. WU X, Sun Y, Yang H, Wang J, et al
    Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
    Lancet. 2024 Oct 15:S0140-6736(24)02135-4. doi: 10.1016/S0140-6736(24)02135.
    PubMed     Abstract available
    
    
    
37. SUN C, Ma D
    Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2024 Oct 15:S0140-6736(24)02196-2. doi: 10.1016/S0140-6736(24)02196.
    PubMed    
    
    
    
38. THE LANCET
    Endometriosis: addressing the roots of slow progress.
    Lancet. 2024;404:1279.
    PubMed    
    
    
    September 2024
39. SHARP G, Randhawa A, Fernando AN
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01710-0. doi: 10.1016/S0140-6736(24)01710.
    PubMed    
    
    
    
40. BROWN L, Hunter MS, Crandall CJ, Connors HJ, et al
    Reflections on The Lancet menopause Series - Authors' reply.
    Lancet. 2024 Sep 25:S0140-6736(24)01712-4. doi: 10.1016/S0140-6736(24)01712.
    PubMed    
    
    
    
41. STUCKEY BGA
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01709-4. doi: 10.1016/S0140-6736(24)01709.
    PubMed    
    
    
    
42. XIAO Y, Shen M, Chen X
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01711-2. doi: 10.1016/S0140-6736(24)01711.
    PubMed    
    
    
    
43. GENNIGENS C
    Hope emerging in the locally advanced cervical cancer landscape.
    Lancet. 2024 Sep 13:S0140-6736(24)01918-4. doi: 10.1016/S0140-6736(24)01918.
    PubMed    
    
    
    
44. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-
    Lancet. 2024 Sep 13:S0140-6736(24)01808-7. doi: 10.1016/S0140-6736(24)01808.
    PubMed     Abstract available
    
    
    August 2024
45. RYDELIUS J, Hognert H, Kopp-Kallner H, Brandell K, et al
    First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024;404:864-873.
    PubMed     Abstract available
    
    
    
46. MOSESON H, Gerdts C
    Expanding access, reducing burdens, and improving person-centred care in abortion.
    Lancet. 2024;404:826-827.
    PubMed    
    
    
    
47. FIGUERAS F, Rial-Crestelo M, Gratacos E
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial - Authors' reply.
    Lancet. 2024;404:751-752.
    PubMed    
    
    
    
48. GILES-CLARK HJ, Rolnik DL, Hodges RJ, Skinner SM, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750.
    PubMed    
    
    
    
49. BACON I, Hezelgrave NL, Cerdeira AS, Mylrea-Foley B, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750-751.
    PubMed    
    
    
    
50. KAMIHARA Y, Nagase H, Ishikawa H
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749-750.
    PubMed    
    
    
    
51. MEIJERINK L, Terstappen F, Depmann M, Bekker M, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749.
    PubMed    
    
    
    
52. BORNSTEIN E, Vintzileos A
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:748-749.
    PubMed    
    
    
    
53. WEI F, Georges D, Man I, Baussano I, et al
    Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.
    Lancet. 2024;404:435-444.
    PubMed     Abstract available
    
    
    
54. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    PubMed    
    
    
    July 2024
55. ALVES L
    New abortion bill in Brazil sparks backlash.
    Lancet. 2024;404:17.
    PubMed    
    
    
    June 2024
56. HO VNA, Pham TD, Nguyen NT, Wang R, et al
    Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.
    Lancet. 2024 Jun 26:S0140-6736(24)00756-6. doi: 10.1016/S0140-6736(24)00756.
    PubMed     Abstract available
    
    
    
57. JAFFE S
    US Supreme Court protects access to abortion medication.
    Lancet. 2024;403:2679-2680.
    PubMed    
    
    
    
58. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    PubMed     Abstract available
    
    
    
59. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    PubMed     Abstract available
    
    
    May 2024
60. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    PubMed     Abstract available
    
    
    
61. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    PubMed    
    
    
    April 2024
62. STRAND TA, McCann A, Kvestad I, Chandyo RK, et al
    Vitamin B12 deficiency in pregnant women - Authors' reply.
    Lancet. 2024;403:1450.
    PubMed    
    
    
    
63. SEN S
    Vitamin B12 deficiency in pregnant women.
    Lancet. 2024;403:1449-1450.
    PubMed    
    
    
    March 2024
64. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    PubMed     Abstract available
    
    
    
65. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    PubMed    
    
    
    
66. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
    Lancet. 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
    PubMed     Abstract available
    
    
    
67. TEWARI KS, Monk BJ
    Immunotherapy plus chemoradiotherapy in cervical cancer management.
    Lancet. 2024 Mar 20:S0140-6736(24)00468-9. doi: 10.1016/S0140-6736(24)00468.
    PubMed    
    
    
    
68. HEISLER M, Mitchell N, Arey W, Erenberg M, et al
    US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies.
    Lancet. 2024 Mar 19:S0140-6736(24)00551-8. doi: 10.1016/S0140-6736(24)00551.
    PubMed    
    
    
    
69. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
    Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
    Lancet. 2024;403:1081-1082.
    PubMed    
    
    
    
70. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
    Optimising health after early menopause.
    Lancet. 2024;403:958-968.
    PubMed     Abstract available
    
    
    
71. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available
    
    
    
72. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
    Promoting good mental health over the menopause transition.
    Lancet. 2024;403:969-983.
    PubMed     Abstract available
    
    
    
73. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
    An empowerment model for managing menopause.
    Lancet. 2024;403:947-957.
    PubMed     Abstract available
    
    
    
74. HAWKES P, Scott J, Hickey M
    500 Strong: celebrating older women's bodies in menopause and beyond.
    Lancet. 2024;403:894-903.
    PubMed    
    
    
    
75. SAMARASEKERA U
    Martha Hickey: responding to the complexity of menopause.
    Lancet. 2024;403:893.
    PubMed    
    
    
    
76. THE LANCET
    Time for a balanced conversation about menopause.
    Lancet. 2024;403:877.
    PubMed    
    
    
    
77. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    PubMed     Abstract available
    
    
    
78. ZAROCOSTAS J
    Renewed calls to scale-up cervical cancer screening.
    Lancet. 2024;403:797.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.